{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:02Z","timestamp":1753889942127,"version":"3.41.2"},"reference-count":26,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: For the Asian patients with STEMI undergoing PCI, ACEIs are known to have a better outcome than ARBs. However, there is limited evidence to suggest so. Methods: Among the STEMI registry consist of 1142 Korean patients, we compared the MACE, the composite of myocardial infarction, stoke, death, admission for heart failure, and target vessel revascularization, between the ACEI and ARB groups (Set 1). Further, we defined adequate medication as the administration of a dose equal to or higher than the initiation dose of ACEI according to the heart failure guideline recommendation with a mandatory addition of beta-blockers, and compared the outcomes between the inadequate and adequate medication groups (Set 2). Propensity score matching was used to eliminate difference. Results: In the Set 1 comparison, patients in the ACEI group had a better outcome than those in the ARB group for both whole and matched populations (whole and matched population: Cox regression hazard ratio [HR], 0.645 and 0.535; 95% confidence interval [CI], 0.440\u20130.944 and 0.296\u20130.967; p = 0.024 and p = 0.039, respectively). In the Set 2 comparison for the whole population, patients in the inadequate medication group had more MACE than those in the adequate medication group (HR, 0.673; 95% CI, 0.459\u20130.985; p = 0.042). However, no difference was observed after propensity score matching (HR, 1.023; 95% CI, 0.654\u20131.602; p = 0.919). Conclusion: ACEIs might be a better choice than ARBs after primary revascularization. However, this study\u2019s findings suggest that early ACEI dose escalation combined with beta-blocker use may not improve prognosis.<\/jats:p>","DOI":"10.31083\/j.rcm2301018","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T08:58:19Z","timestamp":1642237099000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of optimal renin-angiotensin-system inhibition strategy in Asian patients with STEMI after primary myocardial revascularization"],"prefix":"10.31083","volume":"23","author":[{"given":"Hye-Jin","family":"Park","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, 05505 Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jun","family":"Jang","sequence":"first","affiliation":[{"name":"Division of Cardiology, Sejong General Hospital, 21080 Bucheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, CHA Ilsan Medical Center, CHA University School of Medicine, 10414 Goyang, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Woo","family":"Kwon","sequence":"first","affiliation":[{"name":"Division of Cardiology, Inha University Hospital, 22332 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Don","family":"Park","sequence":"first","affiliation":[{"name":"Division of Cardiology, Inha University Hospital, 22332 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Gyu","family":"Kong","sequence":"first","affiliation":[{"name":"Division of Cardiology, Soon Chun Hyang University Bucheon Hospital, 14584 Bucheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Suh","sequence":"first","affiliation":[{"name":"Division of Cardiology, Soon Chun Hyang University Bucheon Hospital, 14584 Bucheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyung Chun","family":"Oh","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, 21564 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeonggeun","family":"Moon","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, 21564 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyounghoon","family":"Lee","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, 21564 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Chol","family":"Kang","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, 21564 Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000; 355: 1575\u20131581.","DOI":"10.1016\/S0140-6736(00)02212-1"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J, K\u00f8ber L, Maggioni AP, et al. Valsartan, Captopril, or both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or both. New England Journal of Medicine. 2003; 349: 1893\u20131906.","DOI":"10.1056\/NEJMoa032292"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360: 752\u2013760.","DOI":"10.1016\/S0140-6736(02)09895-1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ko D, Azizi P, Koh M, Chong A, Austin P, Stukel T, et al. Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. Open Heart. 2019; 6: e001010.","DOI":"10.1136\/openhrt-2019-001010"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. Journal of the American College of Cardiology. 2001; 38: 1402\u20131408.","DOI":"10.1016\/S0735-1097(01)01562-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Byun JK, Choi BG, Rha S, Choi SY, Jeong MH. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Atherosclerosis. 2018; 277: 130\u2013135.","DOI":"10.1016\/j.atherosclerosis.2018.08.038"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kim YH, Her A, Jeong MH, Kim B, Lee S, Hong S, et al. Comparison between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type i Receptor Blockers in ST-Segment Elevation Myocardial Infarction after Successful Percutaneous Coronary Intervention with Drug-Eluting Stents. Cardiovascular Drugs and Therapy. 2019; 33: 55\u201367.","DOI":"10.1007\/s10557-018-6841-7"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018; 39: 119\u2013177.","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"O\u2019Kane KP, Webb DJ, Collier JG, Vallance PJ. Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. British Journal of Clinical Pharmacology. 1994; 38: 311\u2013315.","DOI":"10.1111\/j.1365-2125.1994.tb04359.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin i converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circulation Research. 1992; 71: 137\u2013144.","DOI":"10.1161\/01.RES.71.1.137"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine. 2000; 342: 145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate \u2018EUROPA\u2019 story. Drugs. 2009; 69: 265\u2013277.","DOI":"10.2165\/00003495-200969030-00003"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114: 838\u2013854.","DOI":"10.1161\/CIRCULATIONAHA.105.594986"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the at2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. Journal of Leukocyte Biology. 2005; 78: 195\u2013201.","DOI":"10.1189\/jlb.1204715"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777\u2013781.","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine. 2008; 359: 2456\u20132467.","DOI":"10.1056\/NEJMoa0805450"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Review of Cardiovascular Therapy. 2013; 11: 705\u2013717.","DOI":"10.1586\/erc.13.42"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ferrari R. RAAS inhibition and mortality in hypertension. Global Cardiology Science & Practice. 2013; 2013: 269\u2013278.","DOI":"10.5339\/gcsp.2013.34"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Jung C, Els\u00e4sser A. Update ESC Guideline 2017 - Acute Myocardial Infarction (STEMI). Deutsche Medizinische Wochenschrift. 2018; 143: 797\u2013801.","DOI":"10.1055\/a-0494-0341"},{"key":"ref21","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: e362\u2013e425."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Maggioni AP, Anker SD, Dahlstr\u00f6m U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2013; 15: 1173\u20131184.","DOI":"10.1093\/eurjhf\/hft134"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. The American Journal of Medicine. 2014; 127: 939\u2013953.","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. \u0392-Blockers and Mortality after Acute Myocardial Infarction in Patients without Heart Failure or Ventricular Dysfunction. Journal of the American College of Cardiology. 2017; 69: 2710\u20132720.","DOI":"10.1016\/j.jacc.2017.03.578"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, et al. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: a Meta-Analysis. Circulation. Heart Failure. 2017; 10: e003956.","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Park K, Kim Y, Kim K, Lee S, Park T, Lee S, et al. The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling. ESC Heart Failure. 2018; 5: 354\u2013363.","DOI":"10.1002\/ehf2.12249"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/1\/10.31083\/j.rcm2301018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:24:37Z","timestamp":1732728277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/1\/10.31083\/j.rcm2301018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S1530-6550(22)00305-2"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2301018","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"18"}}